{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:21:22Z","timestamp":1790990482922,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.lanwpc.2025.101464","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T19:33:22Z","timestamp":1737228802000},"page":"101464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Yuji","family":"Hiromatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoyo","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-7859","authenticated-orcid":false,"given":"Tomoko","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-8271","authenticated-orcid":false,"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2025.101464_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.lanwpc.2025.101464_bib2","article-title":"Prevalence, incidence, and clinical characteristics of thyroid eye disease in Japan","volume":"8","author":"Watanabe","year":"2023","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.lanwpc.2025.101464_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanwpc.2025.101464_bib4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/OPX.0b013e3181ce5702","article-title":"Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases","volume":"87","author":"Kozaki","year":"2010","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.lanwpc.2025.101464_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.beem.2011.10.004","article-title":"Ethnic differences in the clinical presentation of Graves' ophthalmopathy","volume":"26","author":"Chng","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.lanwpc.2025.101464_bib6","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.lanwpc.2025.101464_bib7","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib8","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B\u00a0cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib9","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanwpc.2025.101464_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanwpc.2025.101464_bib12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.lanwpc.2025.101464_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.lanwpc.2025.101464_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"European Group on Graves","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ophtha.2011.07.011","article-title":"Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study","volume":"119","author":"Dolman","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.lanwpc.2025.101464_bib16","series-title":"Common Terminology criteria for adverse events (CTCAE)","year":"2010"},{"key":"10.1016\/j.lanwpc.2025.101464_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib18","series-title":"Diagnostic criteria and treatment guidelines for Graves' disease malignant ocular protrusion (thyroid eye disease)","year":"2023"},{"key":"10.1016\/j.lanwpc.2025.101464_bib19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10384-015-0410-4","article-title":"Changes of orbital tissue volumes and proptosis in patients with thyroid extraocular muscle swelling after methylprednisolone pulse therapy","volume":"59","author":"Higashiyama","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1507\/endocrj.EJ16-0038","article-title":"Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy","volume":"63","author":"Ueda-Sakane","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.lanwpc.2025.101464_bib21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","article-title":"Quality of life in a German graves orbitopathy population","volume":"152","author":"Ponto","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lanwpc.2025.101464_bib24","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression","volume":"35","author":"Ugradar","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.lanwpc.2025.101464_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/thy.2023.0466","article-title":"A\u00a0prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease","volume":"34","author":"Douglas","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.lanwpc.2025.101464_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.lanwpc.2025.101464_bib27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ophtha.2024.01.023","article-title":"Glycemic trends in thyroid eye disease (TED) patients treated with teprotumumab in 3 clinical trials","volume":"131","author":"Smith","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.lanwpc.2025.101464_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/WNO.0000000000001994","article-title":"Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy","volume":"44","author":"Tamhankar","year":"2024","journal-title":"J Neuro Ophthalmol"}],"updated-by":[{"DOI":"10.1016\/j.lanwpc.2025.101607","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266660652500001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266660652500001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T01:42:53Z","timestamp":1750470173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266660652500001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"alternative-id":["S266660652500001X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101464","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.lanwpc.2025.101607","asserted-by":"object"}]},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101464"}}